TKNO · Alpha Teknova, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $40.52M | $37.74M | $36.68M | $41.42M | $31.30M |
| Cost of Revenue | $27.08M | $30.51M | $26.39M | $23.94M | $13.54M |
| Gross Profit | $13.44M | $7.23M | $10.30M | $17.48M | $17.75M |
| R&D | $2.20M | $2.76M | $5.57M | $7.74M | $1.51M |
| SG&A | $20.32M | $23.15M | $25.45M | $28.30M | $8.21M |
| Total Operating Expenses | $30.42M | $33.38M | $45.86M | $67.14M | $13.09M |
| D&A | $6.34M | $6.58M | $5.66M | $3.17M | $2.04M |
| Operating Income | ($16.98M) | ($26.15M) | ($35.56M) | ($49.66M) | $4.66M |
| Interest Expense | - | - | - | - | - |
| Income Tax | $58.0K | ($88.0K) | ($298.0K) | ($1.92M) | $1.16M |
| Net Income | ($17.26M) | ($26.75M) | ($36.78M) | ($47.47M) | $3.57M |
| EPS - Basic | ($0.32) | ($0.57) | ($1.16) | ($1.69) | $0.17 |
| EPS - Diluted | ($0.32) | ($0.57) | ($1.16) | ($1.69) | $0.16 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.91M | $3.71M | $28.48M | $42.24M | $87.52M |
| Accounts Receivable | $4.62M | $4.31M | $3.95M | $4.26M | $4.67M |
| Inventory | $7.05M | $6.80M | $11.59M | $12.25M | $5.39M |
| Accounts Payable | $1.38M | $825.0K | $1.49M | $2.45M | $2.25M |
| Current Assets | $34.51M | $42.78M | $45.66M | $61.14M | $101.20M |
| Total Assets | $103.58M | $118.77M | $128.59M | $152.26M | $166.51M |
| Current Liabilities | $7.54M | $11.21M | $8.88M | $10.88M | $7.74M |
| Long-term Debt | $13.12M | $9.44M | $13.25M | $21.98M | $11.87M |
| Total Liabilities | $34.81M | $36.38M | $38.55M | $52.38M | $23.31M |
| Stockholders' Equity | $68.78M | $82.39M | $90.04M | $99.89M | $143.20M |
| Retained Earnings | ($135.79M) | ($118.53M) | ($91.79M) | ($55.01M) | ($7.54M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($8.65M) | ($12.39M) | ($18.81M) | ($27.40M) | $2.50M |
| Investing Cash Flow | $10.70M | ($27.27M) | ($7.74M) | ($28.15M) | ($1.74M) |
| Financing Cash Flow | $151.0K | $14.89M | $12.80M | $10.27M | ($1.60M) |
| CapEx | $1.15M | $1.13M | $7.93M | $28.15M | $5.47M |
| Free Cash Flow | ($9.79M) | ($13.52M) | ($26.75M) | ($55.55M) | ($2.96M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 33.2% | 19.2% | 28.1% | 42.2% | 56.7% |
| Operating margin | -41.9% | -69.3% | -96.9% | -119.9% | 14.9% |
| EBITDA margin | -26.2% | -51.8% | -81.5% | -112.3% | 21.4% |
| Net margin | -42.6% | -70.9% | -100.3% | -114.6% | 11.4% |
| Free cash flow margin | -24.2% | -35.8% | -72.9% | -134.1% | -9.5% |
| FCF / Net income | 0.57 | 0.51 | 0.73 | 1.17 | -0.83 |
| R&D / Revenue | 5.4% | 7.3% | 15.2% | 18.7% | 4.8% |
| SG&A / Revenue | 50.1% | 61.3% | 69.4% | 68.3% | 26.2% |
| Effective tax rate | - | - | - | - | 24.5% |
| Return on assets | -16.7% | -22.5% | -28.6% | -31.2% | 2.1% |
| Return on equity | -25.1% | -32.5% | -40.9% | -47.5% | 2.5% |
| Return on invested capital | -16.4% | -22.5% | -27.2% | -32.2% | 2.3% |
| Liquidity | |||||
| Current ratio | 4.58 | 3.82 | 5.14 | 5.62 | 13.07 |
| Quick ratio | 3.64 | 3.21 | 3.84 | 4.50 | 12.37 |
| Cash ratio | 0.78 | 0.33 | 3.21 | 3.88 | 11.30 |
| Leverage | |||||
| Debt / Equity | 0.19 | 0.11 | 0.15 | 0.22 | 0.08 |
| Debt / Assets | 0.13 | 0.08 | 0.10 | 0.14 | 0.07 |
| Debt / EBITDA | - | - | - | - | 1.77 |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.51 | 1.44 | 1.43 | 1.52 | 1.16 |
| Liabilities / Assets | 0.34 | 0.31 | 0.30 | 0.34 | 0.14 |
| Efficiency | |||||
| Asset turnover | 0.39 | 0.32 | 0.29 | 0.27 | 0.19 |
| Inventory turnover | 3.84 | 4.49 | 2.28 | 1.96 | 2.51 |
| Days sales outstanding | 42d | 42d | 39d | 38d | 54d |
| Days inventory outstanding | 95d | 81d | 160d | 187d | 145d |
| Days payable outstanding | 19d | 10d | 21d | 37d | 61d |
| Cash conversion cycle | 118d | 113d | 179d | 187d | 139d |
| Valuation | |||||
| P / E | - | - | - | - | 128.0x |
| P / B | 3.0x | 4.7x | 1.3x | 1.6x | 0.5x |
| P / S | 5.0x | 10.3x | 3.2x | 3.8x | 2.5x |
| EV / EBITDA | - | - | - | - | 0.3x |
| Growth | |||||
| Revenue growth (YoY) | 7.4% | 2.9% | -11.4% | 32.3% | - |
| Revenue CAGR (3y) | -0.7% | 6.4% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 85.9% | -29.8% | -41.1% | -1.6% | - |
| Operating income growth (YoY) | 35.1% | 26.5% | 28.4% | - | - |
| Net income growth (YoY) | 35.5% | 27.3% | 22.5% | - | - |
| EPS growth (YoY) | 43.9% | 50.9% | 31.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 27.5% | 49.5% | 51.8% | -1776.0% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -16.5% | -8.5% | -9.9% | -30.2% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$40.52M totalLab Essentials$31.04M · 76.6%
Clinical Solutions$7.65M · 18.9%
Other Product$1.83M · 4.5%
Geographic
$40.52M totalUS$38.25M · 94.4%
Non Us$2.27M · 5.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.21
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Alpha Teknova against the 5 most active filers in the same SIC group.